Abstract

Objective: Evidence exists for the presence of a renin–angiotensin system (RAS) in the pancreas. The aims of this study were to prove the presence of an intrinsic RAS in the human pancreas and to analyse the role of such an RAS in pancreatic endocrine tumours (PETs).

Methods: Gene expression of key RAS components (angiotensinogen and angiotensin II receptors, namely AT1 and AT2) was investigated in human pancreas and in PETs by semi-quantitative RT-PCR and immunohistochemistry.

Results: Expression of mRNAs of RAS components was found in human pancreas and in PETs. Data from semi-quantitative RT-PCR analysis demonstrated an increase in the mRNA expression of angiotensinogen and AT2 receptor in PETs when compared with that in normal pancreas. By immunohistochemistry, angiotensinogen protein was predominantly localized in the pancreatic islets while AT1 receptor protein was in the pancreatic ducts.

Conclusions: The data support the notion of the existence of an intrinsic RAS in the human pancreas. It also indicates, for the first time, that such a local pancreatic RAS is subject to regulation by PETs and its significant change may have pathophysiological relevance in patients with PETs.

European Journal of Endocrinology 146 567–572

Introduction

The circulating renin–angiotensin system (RAS) is well known to play important roles in the nervous, cardiovascular and renal systems. The principal hormone of the RAS, angiotensin II, is involved in the regulation of blood pressure, aldosterone secretion and electrolytes as well as fluid homeostasis (1–3). Angiotensin II is spliced from its liver-derived precursor angiotensinogen by the action of an enzyme, renin, secreted by the juxtaglomerular cells in the kidney (4). The hormone acts via the interaction with its specific angiotensin receptors such as AT1 and AT2 (5). In addition to the circulating RAS, major components of the RAS have been shown in numerous tissues/organs of the body like the brain, heart, kidneys, adrenals and gonads (6). These locally generated angiotensins may add to, or differ from, the actions of the circulating RAS through a paracrine/autocrine pathway. Of great interest is the recent evidence for the presence of different components of an RAS in the pancreas of the rat, mouse and dog (7–9). Such an intrinsic, angiotensin-generating RAS has a potential role in finely regulating exocrine and/or endocrine functions of the pancreas (10). In the human pancreas, the expression of an RAS has only been demonstrated in autopsy materials by Tahmasebi et al. (11). Thus, the role of an RAS in the human pancreas, with particular reference to some pancreatic diseases such as pancreatic endocrine tumour (PET), is largely undefined.

The pancreatic islet is the classical endocrine unit in the pancreas. PETs are endocrine tumours arising from cells in the pancreatic islets (12). They account for slightly more than 10% of primary pancreatic tumours. This group of tumours is classified according to the clinical and biochemical evidence of hormones they produce. For instance, they can be named as insulinoma, glucagonoma, gastrinoma and so on (12). Among them, insulinoma is the most commonly encountered PET in clinical diagnosis. The tumours present an important challenge to the endocrinologist because of their hormonal manifestations, uncertain malignancy and potential lethality (13). Some interactions may exist among the classical endocrine unit in the pancreas, islet cells and the newly recognized RAS. However, the involvement of a pancreatic RAS in patients with PETs has never been reported in the English language literature.

In this study, we analysed the regulation and localization of the different components of the RAS in normal
human pancreas. In addition, we examined, for the first time, the association between pancreatic RAS and its clinical implications for PETs. We employed biopsy materials for the present study in order to avoid the autolysis that may be encountered in autopsy specimens.

Materials and methods

Preparation of tissues from PETs

Fresh tissues were collected from five patients who underwent resection for insulinomas. In each of these patients, non-tumour pancreatic tissues were also sampled at the Department of Surgery at the University of Hong Kong. Informed consent was obtained from each patient and human ethics approval was sought from the Clinical Research Ethics Committee. These freshly collected specimens were snap frozen in liquid nitrogen and stored at −70°C. The other portions of the PETs were fixed in formalin and embedded in paraffin. In addition, formalin-fixed paraffin-embedded blocks of non-tumour pancreases were retrieved from five patients who underwent resection for diseases not related to the pancreas. Haematoxylin and eosin-stained sections from all the frozen and paraffin-embedded tissues were prepared for the confirmation of the diagnosis of PET and the presence of islets in the non-tumour pancreases. The PETs were proven to be insulin-secreting by both elevated serum insulin levels and tissue expression of insulin (12).

Semi-quantitative RT-PCR analysis of RAS expression

Total RNA of the frozen samples (normal and tumour pancreases) was isolated according to the acid guanidinium thiocyanate–phenol–chloroform protocol (14). Briefly, tissues were homogenized in 4 mol/l guanidinium thiocyanate solution and repeatedly extracted with water-saturated phenol. After extraction with chloroform, RNA was precipitated with isopropanol. The resultant pellet was finally resuspended in water treated with diethylpyrocarbonate. The total RNA was separated by gel electrophoresis and quantified by spectrophotometry. The extracted RNA was then used for first-strand cDNA synthesis using Superscript II transcriptase (GIBCO-BRL, Grand Island, NY, USA) in a final volume of 20 μl. After incubation at 42°C for 1 h, the reaction mixture was treated with RNase H before proceeding to PCR analysis. All the RNAs were free of DNA contamination by RT-PCR without addition of reverse transcriptase.

Two preliminary experiments were performed before semi-quantitative RT-PCRs of RAS component genes were analysed as described previously (15, 16). To validate the linearity of PCR product accumulation with increasing number of PCR cycles, aliquots containing fixed amounts of cDNA mixture were subjected to amplification for several different PCR cycles, from 20 to 40 cycles. All samples were analysed for both RAS genes and β-actin gene in the logarithmic phase of the amplification reactions. Fixed amounts of cDNA and optimal PCR cycles were directly employed for individual PCR amplification of human RAS component genes (angiotensinogen, AT1, and AT2 receptors) and human β-actin genes as employed previously (17). PCR reactions were carried out in a volume of 50 μl containing the corresponding sense and antisense primer sequences using the PCR Reagent System (GIBCO-BRL). The PCR conditions were 26–28 cycles of denaturing, at 94°C for 1 min, annealing, at 62°C for 1 min, and elongating at 72°C for 2 min. All PCR products were separated on 2% agarose gel electrophoresis. The amplified DNA bands were detected using ethidium bromide staining and quantified with an image analyser (Image Quant; Molecular Dynamics, Sunnyvale, CA, USA).

Statistical analysis

Results of the RT-PCRs are expressed as means ± S.E.M. (n = 5 for each group). The mRNA expression of the various components of the RAS in normal pancreases and PETs was normalized as a percentage of relative expression of RAS components to that of β-actin. Comparison of differences between individual mean values were made using Student’s t-test. Values of P < 0.05 vs respective control group were considered statistically significant.

Immunohistochemical localization of RAS components

Immunohistochemical study was conducted on 5 μm-thick paraffin-embedded sections from normal pancreases and PETs by the avidin–biotin–peroxidase complex method. They were de-paraffinized with xylene and rehydrated through graded concentrations of alcohol. The sections were then treated with microwave irradiation at 95°C in 10 mmol/l citrate buffer for 15 min. They were washed in water, rinsed with Tris-buffered saline (TBS) and treated with 3% hydrogen peroxide in methanol for 10 min at room temperature to block the intrinsic peroxidase activity. The sections were again washed with water and rinsed with TBS. Ten per cent normal serum was then added at room temperature for 10 min. Primary antibodies were added to the sections either with anti-angiotensinogen serum diluted at 1:400 as described previously (7, 18) or with anti-AT1 receptor serum (Santa Cruz Biotech Inc., Santa Cruz, CA, USA) diluted at 1:200 as employed previously (16). The sections were incubated in a moist chamber overnight at 4°C. The slides were again washed three times in TBS for 3 min. Biotinylated IgG and pre-incubated (30 min at room temperature) avidin–biotin complex (1:100)
(Amersham International, Amersham, Bucks, UK) were added for 30 min at 37°C. They were washed in TBS followed by the development in freshly prepared 3,3′-diaminobenzidine/hydrogen peroxide solution for 10 min at room temperature. The sections were then washed in water, counter-stained with Mayer’s haematoxylin for 1 min at room temperature, dehydrated, cleaned and mounted. Brown cytoplasmic staining was regarded as a positive signal. For negative control experiments, the specific angiotensinogen and AT1 receptor antibodies were preadsorbed with excesses of their peptide antigens.

Results

Expression of RAS components in normal pancreas and PETs

The mRNA expression of angiotensinogen was noted in normal pancreas and PETs (Fig. 1). The RT-PCR product was 374 bp, as shown in a representative image of gel analysis. The relative expression of mRNAs for angiotensinogen to β-actin in PETs was increased by approximately 1.5-fold when compared with those in normal pancreas. The expression of AT1 receptor mRNA was found in normal pancreas and PETs (Fig. 2). The RT-PCR product was 340 bp. The relative expression of AT1 receptor in PETs was down-regulated to approximately two-thirds when compared with those in normal pancreas. On the other hand, the expression of AT2 receptor mRNA was also detected in normal pancreas and PETs (Fig. 3). The RT-PCR product was 406 bp. The relative expression of mRNAs for AT2 receptor was increased by 1.3-fold when compared with those in normal pancreas, as demonstrated by image analysis.
Localization of RAS components in normal pancreas and PETs

In normal pancreas, immunoreactivity for angiotensinogen appeared to be localized predominantly in the pancreatic islets (Fig. 4A). Focal immunostaining for angiotensinogen was also found in the cytoplasm of the epithelial cells from pancreatic ductal epithelium (Fig. 4C). For AT$_1$ receptor protein, the expression was localized to the pancreatic ducts (Fig. 4B and D). In PETs, angiotensinogen and AT$_1$ receptor proteins were not detected in pancreatic islets (Fig. 4C and D). The specificity of the immunostaining for angiotensinogen and AT$_1$ receptor was validated by the negative signal when the specific antibodies were preadsorbed with an excess of their respective peptide antigen (data not shown).

Discussion

There has been a steady stream of studies of the potential role of a local RAS in the non-human pancreas. The target for the pancreatic RAS could provide an insight into future management of several pancreatic diseases including acute pancreatitis, diabetes mellitus, cystic fibrosis and pancreatic cancer (19). Nevertheless, there is a lack of solid evidence for the presence of a local RAS in the human pancreas. The only piece of evidence available in the English language literature demonstrated the presence of AT$_1$ receptor in human pancreas by means of immunohistochemistry (11). In the present investigation, we examined the different components of the RAS in the pancreas by immunohistochemistry and semi-quantitative RT-PCR. The mRNAs of angiotensinogen and angiotensin II receptors (AT$_1$ and AT$_2$) were observed in human pancreas. Angiotensinogen protein was found predominantly in pancreatic islet and AT$_1$ receptor was in the pancreatic ducts. Thus, an intrinsic RAS exists in the human pancreas.

Insulinoma is the most common type of PET. Unfortunately, no human insulinoma cell line is available for experimental analysis at the moment. A rat insulinoma cell line has been employed for the analysis of the properties of the pancreatic islet and PETs (20). The expression of genes encoding multiple peptide hormones including insulin, glucagon and somatostatin normally noted in the pancreatic islets, has been demonstrated in the rat insulinoma cell line (20). Moreover, the expression of angiotensinogen gene was found in rat insulinoma cell lines (21). The expression was regulated by glucocorticoid and thyroid hormone (22). This piece of evidence suggests that, at least in an animal model, an RAS may be involved in the pathogenesis of PETs. In the current study, we demonstrated, for the first time, an increase of angiotensinogen mRNA in insulinomas from human pancreas. Multi-hormone production in human PETs has been demonstrated by immunohistochemistry in our laboratories (12). It is tempting to relate the multi-potentiality of neoplastic islet cells to the developmental pathway of differentiation of islet cells. They are probably derived from a common stem cell of endodermal origin. The demonstration of multi-hormone production allows the detection of the diverse secretory potential of PETs. In the previous experiment, our immunohistochemical investigation showed evidence for multi-hormone production in 18% of PETs (12). In this study, PETs were shown to co-express insulin and angiotensinogen. The percentage for the detection of multi-hormones would probably rise if the number of hormones being tested were increased. It is plausible to suggest that the potential for protein complex and clinical manifestation should be noted in PETs.

In this study, the expression of receptors for angiotensin II was altered in patients with insulinoma. AT$_1$ receptor mRNA was found to be down-regulated in PETs and AT$_1$ receptor protein was not detected in PETs by immunohistochemistry. In contrast, mRNAs of angiotensinogen and AT$_2$ receptor were up-regulated in PETs. However, we could not rule out the possibility...
that an increase of angiotensinogen was due to the aberrant expression by the pancreatic ducts with no expression in the endocrine neoplastic tissue. Previous studies have shown that pancreas is one of the few tissues that contains a significant proportion of the AT2 receptor as compared with that of AT1 receptor (23–25). In view of this fact, it is likely that angiotensin II, increased via the up-regulation of its precursor angiotensinogen, could act on AT2 receptors in patients with PETs. A role for the up-regulation of the RAS in patients with PETs has yet to be determined. Blood flow to the pancreatic islets is regulated through a complex interaction of hormonal and nervous influences. The resultant islet blood perfusion controls the metabolism of the endocrine cells and the release of the islet hormones. One of the characteristics of PETs is their prominent vascular component. Angiotensin II has its principal action on the blood vessels. Interestingly, the association between pancreatic RAS and pancreatic blood flow has been recently reviewed in our laboratory (10). The angiotensin II produced in the PET may regulate the blood flow and hence stimulating islet hormonal secretion in the tumour.

It is worth noting that we demonstrated an increase in angiotensinogen mRNA whereas the angiotensinogen protein could not be detected in PETs. Two reasons may be postulated for this discrepancy: (i) PETs may contain abnormal angiotensinogen protein that could not be detected by the immunohistochemical approach, and (ii) the angiotensinogen protein may be carried away by the prominent vascular supply in the tumour at a high rate such that its low level in the tumour cannot be detected. Additional experimental data are required to fully elucidate the pathophysiological aspect of the action of the pancreatic RAS in PETs.

In summary, the present study provides solid evidence for the presence of a local RAS in the human pancreas. In addition, the different components of the RAS were subject to change in PETs. These changes may have physiological and pathophysiological relevance in PETs.

**Acknowledgements**

The authors would like to gratefully acknowledge support by Competitive Earmarked Research Grants from the Research Grants Councils of Hong Kong (Project No: CUHK 4116/01M and CUHK 4075/00M) and by Direct Grants from the Chinese University of Hong Kong.
References